Marie Anna Nandeuil

Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD

Dave Singh, Kai Michael Beeh, Brendan Colgan et al. · Respiratory Research · 2019 · 80 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study

Dave Singh, Aida Emirova, Catherine Francisco et al. · Respiratory Research · 2020 · 46 citations · Full text

Medicine, Clinical Sciences, Pharmacology +16

A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients

Dave Singh, Brian Leaker, Malcolm Boyce et al. · Pulmonary Pharmacology & Therapeutics · 2016 · 45 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis

Mirco Govoni, Michele Bassi, Stefano Vezzoli et al. · Respiratory Research · 2020 · 32 citations · Full text

Life Sciences, Molecular Biology, Molecular Medicine +17

Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers

Fabrizia Mariotti, Mirco Govoni, Germano Lucci et al. · International Journal of COPD · 2018 · 30 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14